Europe CIS

Europe CIS provides a broad range of Sterile Focus and Regional Brands while operating a range of manufacturing facilities for Aspen’s own production needs, as well as manufacturing for third parties. Sterile Focus Brands comprise anaesthetics and thrombosis in Russia and the other CIS countries only. Manufacturing activities include active pharmaceutical ingredients (“APIs”) and FDF production and our sites are widely accredited. The prefilled syringe and multi-dose form sites in France and Germany respectively, provide FDF medicines for commercialisation by Aspen and third parties for both domestic and export markets.

Key Countries

France
Germany
Netherlands
Russian Federation
United Kingdom

KEY BRANDS

Brand		Therapeutic category
Diprivan		General anaesthetic
Emla		Local anaesthetic
Imuran		Immunomodulator
Ovestin		Estrogen hormone replacement
Xylocaine		Regional anaesthetic

NUMBER OF PERMANENT EMPLOYEES

2 195

June 2021

2 492

June 2020

STATISTICS

Number of products launched:

1

(2020: Nil)

Number of product recalls:

2

(2020: 3)

Average staff turnover:

11%

(2020: 11%)

Number of work-related fatalities:

Nil

(2020: Nil)

Sales representatives:

149

(2020: 225)

Revenue	2021 R’million	2020 (CER) R’million	Change %
Total Commercial Pharmaceuticals	5 314	5 653	(6)
Regional Brands	1 774	2 170	(18)
Sterile Focus Brands	3 540	3 483	2
Total Manufacturing	8 308	6 438	29
FDF	2 248	707	>100
API Biochem	1 243	1 183	5
API Chemicals	4 817	4 548	6

Total	13 622	12 091	13

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.